

FORM PTO-1449 (REV. 7-88)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1079CON4		SERIAL NO.: 10/056,348	
<b>LIST OF PRIOR ART CITED BY APPLICANT</b> (Use several sheets if necessary)				APPLICANT(S): Ronald BURCH et al.			
				FILING DATE: January 25, 2002		GROUP: 1639	

U.S. PATENT DOCUMENTS									
*EXAMINE R INITIAL	AA	AB	AC	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS									
	AD			DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
									Yes No

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)	
	AE Purdue Discovery Research, Department of Neuropharmacology Study Report "Assessment of the Effects of Combined Administration of Oxycodone and Cox II inhibitors, Celecoxib, Etodolac and Rofecoxib, in the Rat FCA Model of Inflammatory Pain"; July 28, 2003
	AF
	AG
	AH
	AI
	AJ
	AK
	AL
	AM
	AN
	AO
	AP
	AQ
	AR
	AS

EXAMINER		DATE CONSIDERED <div style="text-align: right; font-size: 1.2em;">11/7/05</div>
----------	--	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449  
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:  
200.1079CON4

SERIAL NO.: 10/056,348

## LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S): Ronald BURCH et al.

FILING DATE: January 25,  
2002

GROUP: 1639



## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							Yes	No
	AG							

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	AH	Tanaka et al., "Pharmacological Studies of the New Antiinflammatory Agent 3-Formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one," <i>Arzneim-Forsch/Drug res.</i> 42 (II), Nr. 7, pp. 935-944 (1992)
	AI	Engelhardt et al., "Anti-inflammatory, Analgesic, Antipyretic and Related Properties of Meloxicam, a New Non-steroidal Anti-inflammatory Agent with Favorable Gastrointestinal Tolerance," <i>Inflamm. Res.</i> 44:423-433 (1995)
	AJ	Engelhardt, "Pharmacology of meloxicam, a new non-steroidal anti-inflammatory drug with an improved safety profile through preferential inhibition of COX-2," <i>Brit. J. Rheumatology</i> 1996:35 (suppl. 1): 4-12
	AK	Distel et al., "Safety of Meloxicam: A Global Analysis of Clinical Trials," <i>Brit. J. Rheumatology</i> 1996:35 (suppl. 1):68-77
	AL	Wojtulewski et al., "a Six Month Double-blind Trial to Compare the Efficacy and Safety of Meloxicam 7.5 mg Daily and Naproxen 750 mg Daily in Patients with Rheumatoid Arthritis," <i>Brit. J. Rheumatology</i> 1996:35 (suppl. 1):22-28
	AM	Swingle et al., "Preclinical Pharmacological Studies With Nimesulide," <i>Drugs Exptl. Clin. Res. Vol. X (8-9) pp.</i> 587-597
	AN	Rabasseda, "Nimesulide: A Selective Cyclooxygenase 2 inhibitor Antiinflammatory Drug," <i>Drugs of Today Vol 32, No.5 (1996), p.</i> 365-384
	AO	Siebert et al., "Pharmacological and Biochemical Demonstration of the Role of Cyclooxygenase 2 in Inflammation and Pain," <i>PNAS USA Vol.91 (Dec. 1994) pages</i> 12013-12-17
	AP	Richardson et al., "The Clinical Implications of Inhibition of the Inducible Form of Cyclo-oxygenase," <i>Drug Safety Vol. 15(4), pp.</i> 249-260 (Oct. 1996)
	AQ	

EXAMINER



DATE CONSIDERED

1/7/05

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.